Two Dividend Snowballs, Tested: PG And JNJ After The Price Pain

The "dividend snowball" is a simple enough idea. You buy stocks that pay and grow their dividends, reinvest every payout, add new money each month, and let three compounding forces stack on each other: contributions, reinvested dividends, and dividend growth. It looks slow at first. Then it accelerates.

The competitor headline you've probably seen this month calls two names and promises they're worth rolling into retirement. The trouble with most snowball articles is that they fall in love with the metaphor and skip the hard part: testing whether the cash-flow engine behind the payout can actually survive a bad year, let alone a decade of them.

So let's do that. Johnson & Johnson and Procter & Gamble are the two names most often cited as snowball core holdings. Both are Dividend Aristocrats - companies with 25 or more consecutive years of dividend increases. Both trade at depressed prices after months of selling. Both are supposed to be the reliable half of a retirement income portfolio.

The real question isn't whether they look good on a chart. It's whether the income stream is intact, whether lower prices improve your reinvestment terms, and whether the payout can keep growing as you age into the part of the plan where you need it.

The cash-flow engine at Procter & Gamble

PG's dividend yield sits at roughly 2.96%, with 22 consecutive years of increases and 24 years of total payouts. The payout ratio - dividends as a share of earnings - rests at about 59.5%. That leaves roughly 40% of earnings available for reinvestment, balance sheet repair, or the next annual raise.

Free cash flow over the trailing twelve months stands at $15.15 billion, up nearly 8% year over year. That's what funds the dividend, not the GAAP headline. The company's net debt is $24.2 billion against $15.15 billion in free cash flow, a manageable ratio for a consumer staples business with recurring revenue and pricing power.

Here's where the snowball test gets real. PG just reported its fiscal fourth quarter on July 29 and missed earnings expectations, coming in at $1.43 per share versus a consensus forecast of $1.81. Revenue came in at $21.2 billion, below the $23.3 billion analysts expected. The stock has fallen roughly 9% over the last four months and about 5.6% on a rolling annual basis.

The price pain is real. But what matters for the snowball is whether the cash-flow engine broke or whether the market simply got impatient with a slow-growth consumer company in a tech-driven rally. PG's brands - Tide, Pampers, Crest, Gillette - sell products people buy regardless of the business cycle. The miss was cyclical, not structural. The dividend payout ratio didn't spike. Free cash flow is still growing. The 59.5% payout rate leaves room for the next annual increase even if earnings growth stalls temporarily.

The stock trades at roughly 21 times trailing earnings and 15.8 times EV/EBITDA, below several of its consumer staples peers. That means you can buy more PG shares per dollar of income than you could a year ago. For the snowball, that's a reinvestment advantage, not a reason to step aside.

The cash-flow engine at Johnson & Johnson

JNJ tells a different near-term story. The stock has also sold off - down roughly 6% over 20 days and 5.9% over the last month - but just beat its second-quarter earnings report on July 15. Actual EPS came in at $2.90 versus a forecast of $2.85, and revenue of $25.31 billion topped the $25.02 billion consensus.

The dividend mechanics are solid. A 2.08% yield, 23 consecutive years of increases, and a payout ratio of roughly 60%. Free cash flow stands at $22.61 billion, up 24.4% year over year. That kind of cash-flow acceleration is what keeps dividend growth compounding even when the stock price lags.

JNJ trades at 28.8 times trailing earnings, which looks expensive on the surface. But the forward P/E - based on next year's expected earnings - comes in around 18.3, a meaningful discount to the trailing multiple. That signals the market is pricing in a recovery in normalized earnings after a drag from litigation costs and pharmaceutical patent transitions. If those estimates hold, the forward multiple is actually well below large-cap healthcare peers like Merck at 35 times and AbbVie at 68 times.

The balance sheet is heavier than PG's - total debt of $116.1 billion and a debt-to-equity ratio of 57.7% - but free cash flow of $22.6 billion easily covers both interest and dividends. Net debt after cash is a more tractable $28.3 billion. The cash-flow engine isn't leveraged into trouble; it's just operating at a larger scale with more legacy obligations.

What distinguishes JNJ in the snowball context is that 24.4% free-cash-flow growth rate. Most dividend Aristocrats grow their payouts at 4-6% annually. When free cash flow is accelerating at more than four times that pace, the payout ratio has genuine runway to expand without risk.

The counterargument: these yields are small

The honest objection here is that neither stock is a high-yield name. PG at roughly 3% and JNJ at roughly 2.1% won't fund a retirement on their own. If you're looking for immediate income, names like Realty Income at higher single digits or Pfizer at nearly 7% will dwarf these payouts.

But the snowball isn't about maximizing current yield. It's about maximizing the dividend per share of every stock you own, and letting those growing payouts buy more shares through reinvestment. A stock that cuts its dividend in year eight destroys eight years of compounding. A stock that grows its payout 4-6% per year for twenty years turns a 2-3% starting yield into something far more meaningful on a yield-on-cost basis - that is, the effective yield on your original investment price.

PG and JNJ have demonstrated they can raise their dividends through recessions, market crashes, and inflation cycles. The 2008 financial crisis didn't break either payout. The 2020 pandemic didn't break either payout. Recent earnings misses and price declines haven't broken either payout.

The question that would actually change my view on these names is whether free cash flow turns negative or the payout ratio breaches 80% for an extended period. Neither condition exists today. PG sits at roughly 60%. JNJ sits at roughly 60%. Both have room.

How to use them

If you're building a dividend snowball for retirement, these two names serve different roles in the same machine.

PG is the consumer staples anchor - predictable cash flows, manageable debt, a yield just under 3%, and a track record of compounding even when the stock price is flat. It's the name you reinvest into when it gets cheap, not when it's trending.

JNJ is the healthcare cash-flow compounder - higher free cash flow growth, a lower starting yield, but a forward earnings multiple that suggests the market may be underestimating the normalization ahead. It rewards patience in the same way PG does, just with a different growth profile.

The practical move for an income investor watching the screen turn red is the same for both: check whether the dividend is safe, check whether the price decline means you can buy more future income per dollar, then reinvest. The snowball doesn't get bigger by timing the bottom. It gets bigger by collecting.

What would change the thesis on either name? A sustained break in the dividend streak. A payout ratio that climbs past 80% without a corresponding free-cash-flow recovery. Or a structural shift in their core businesses that makes earnings growth unlikely to resume. None of those conditions are present today.

The income stream is intact. The prices are lower. The reinvestment terms have improved. That's the snowball arithmetic the metaphor is actually trying to describe.